AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04645446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro-ocular gel
Description: Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
Study NCT04645446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Topical gel in multidose formulation to be applied laterally to the forehead twice a day, morning and night for 3 months
Study NCT04232033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibroblast growth factor 21 infusion
Description: Infusion of Fibroblast growth factor 21
Study NCT04232033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion (saline)
Description: Infusion of Saline
Study NCT06471777 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluid removal
Description: Fluid removal during kidney replacement therapy
Study NCT05418296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A novel digital health device
Description: A videogame-generated virtual world designed for the AD/ADRD care dyad.
Study NCT06419478 — intervention group
Intervention type: OTHER
Intervention: postoperative symptoms
Description: Observational study, focusing solely on symptom surveys of patients.
Study NCT06238440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Splint and taping methods
Description: In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape
Study NCT06238440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splint and taping methods
Description: In the control group (CG), a conventional physiotherapy program will be implemented for 2 weeks. A 10-session treatment will be completed using thermal and electrical agents specified in the program prescribed by the physiotherapist.~Splint group: CG + Splint Rigid taping group: CG+ Rigid taping Kinesiotape: CG+ kinesiotape
Study NCT05925946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CURE-DM
Description: 1. This randomized controlled prospective trial will be of 2 years duration where 150 patients with T2DM from urban areas of Delhi will be screened.~2. These subjects will be randomized into two groups by computer-generated randomization list using variable block size.~3. Group A (n, 60, test group)will be received a low-calorie diet along with appropriate exercise counseling; and group B (n, 60, Control group) will be received balanced diet along with exercise advice.
Study NCT05718856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPO-RAs
Description: After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description. Complete blood count including platelet count was done once a week. The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count >250×10\^9/L, the TPO-RAs will stop until the platelet count \<100×10\^9/L.
Study NCT05718856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPO-RAs combining anti-CD 20 monoclonal antibody
Description: After enrollment, all subjects receive TPO-RAs treatment. The initial dose of eltrombopag, hetrombopag and avatrombopag administration were the same as described in arm description.The dose of TPO-RAs was adjusted according to the subject platelet count during the period from week 1 to week 24.~Subjects in TPO-RAs combining anti-CD 20 monoclonal antibody treatment group received single dose infusion of Rituximab 375 mg/m2 within 14 days after enrollment. Subjects weighing less than 30kg will be given Rituximab 100 mg once a week for four times. Ortuzumab at 1000mg/ dose is also recommended for subjects weighing 45kg or greater.~Ps.Participants in the TPO-RAs monotherapy group who have platelet count \< 20×10\^9/L or significant skin and mucosal bleeding at the end of 12 weeks of treatment will be given a single dose of Rituximab 375mg/m2 or Ortuzumab at 1000mg/ dose if weighing 45kg or greater.
Study NCT04822493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling Aid
Description: Women will watch an educational video regarding expectations for delivery and postpartum care in addition to receiving standard care and counseling.
Study NCT06399133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm water intake
Description: Nurses assessed the patients' gag and swallow reflexes in the SG. Patients who experienced nausea after reflex assessment were considered to have positive reflexes and were administered warm water. Packaged water was boiled in a kettle and poured into 200 mL disposable cups. After cooling the water to 38-40°C using a thermometer, patients were instructed to drink it within 3 min.
Study NCT06399133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fiber diet
Description: After initiating oral intake, the patients collaborated with a dietitian to incorporate high-fiber foods containing 30 g of fiber daily into their meal menus.
Study NCT05580822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase for Injection
Description: intra-arterial TNK infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
Study NCT05580822 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intra-arterial saline infusing after successful thrombectomy for patient with acute basilar artery occlusion via support/access catheter
Study NCT04960969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding for 4 weeks
Description: Participants in this group will follow a time-restricted diet for 28 days. Consumption of only non-energy drinks will be allowed for 16 hours. During the 8-hour eating period, there will be no restriction on the content of the diets.
Study NCT05048173 — intervention group
Intervention type: PROCEDURE
Intervention: Sentinel lymph node mapping and biopsy
Description: Sentinel lymph node mapping with indocyanine green dye followed by biopsy if positive
Study NCT06399133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage
Description: Patients in the SG received abdominal massages twice a day, in the morning from 08:00 to 09:00 and in the evening from 19:00 to 20:00, for 15 min per session, starting one day postoperatively.
Study NCT05048173 — intervention group
Intervention type: PROCEDURE
Intervention: Lymphadenectomy
Description: Conventional lymphadenectomy
Study NCT06433973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 1 - CM+LLLT+VISTA
Description: After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts.CM will be placed on the recession defect using minimally invasive technique. LLLT will be applied on the site for 10 sec.
Study NCT06433973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test group 2 - CM+VISTA
Description: After obtaining adequate LA exposed root surfaces of treated teeth are to be scaled with curettes to reduce root convexity and undercuts. Adequate size of CM will be trimmed and applied over the recession defect using minimally invasive technique and secured with sutures.
Study NCT06433973 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group - SCTG+VISTA
Description: Scaling and root planing will be performed and after resolution of periodontal inflammation, root coverage procedure will be done with CTG using minimally invasive access technique.
Study NCT03656029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Participants will smoke as much of the cigarette as they wish
Study NCT03656029 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will smoke a placebo cigarette
Study NCT04762732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPWT
Description: Wound of ALT donor site will be cared under PREVENA™ Incision Management System for 5 days post-operatively.
Study NCT04762732 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional wound care
Description: Wound of ALT donor site will be covered by vaseline gauze coated with tetracycline ointment (Genuine Chemical Pharmaceutical, Tao-Yuan, Taiwan), and layers of gauze.
Study NCT04701177 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AltoidaML
Description: Computerized Complex Instrumental Activities of Daily Living Marker (NMI) (AltoidaML). ClinicalTrials.gov Identifier: NCT02843529
Study NCT05351359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: A mHealth-enabled just-in-time adaptive intervention that is based on the HealthReact system developed by the participating centre at the Faculty of Science of the University of Hradec Kralove. The HealthReact system consists of a server-side application that is connected to the Fitbit server. As such, the system allows for just-in-time text messages triggered by pre-defined context as recorded by the Fitbit wearable monitor. For example, a prompt to take a break from sedentary behaviour can be triggered after 30 sedentary minutes, a suggestion to increase walking cadence can be triggered when continuous, but slow walking is detected, or a motivational message with a specific goal to take more steps to reach their usual daily step count can be triggered when the total daily steps are too low. The mHealth component will be delivered for the entire duration of the study (i.e., 12 months).
Study NCT05665894 — intervention group
Intervention type: DEVICE
Intervention: Hematoma Vaacum Assisted Biopsy
Description: The patient was placed supine and meticulous aseptic measures were applied. Prior procedure local anesthesia (lidocaine 1%) was administered following disinfection. A 5 mm skin incision is performed to guarantee appropriate access for the needle insertion in the hematomas. The evacuation was achieved using a Mammotome® vacuum-assisted system (Devicor Medical Products, Inc., Cincinnati, OH, USA), with an 8-G needle, under the guidance of the same high-resolution US equipment (MyLabTM 9 XP; Esaote SpA, Genoa) for preoperative assessment. Empty-needle function and the tissue-biopsy option is preferred to fragment the fibrotic tissue until the hematoma empties and its walls collapsed. Once VAEv is performed, the postoperative US is carried out and VAEv is repeated until more than 90% evacuations of hematoma volume if no complication occurs.
Study NCT04550637 — intervention group
Intervention type: DRUG
Intervention: Oral apixaban
Description: apixaban (5 mg bid) is given until 12 weeks after surgery
Study NCT05170451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CBD
Description: Topical CBD 50 mg/ml applied in 1mL amounts twice daily
Study NCT05170451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Topical shea butter applied in 1mL amounts twice daily
Study NCT06383832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin tablets oral 10mg/d qd, intervention for 12 weeks.
Study NCT05351359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone counselling
Description: Regular monthly phone calls by trained counsellors support participants in their effort to increase physical activity and reduce sedentary behaviours. The counsellors will use various behaviour change techniques, such as goal-setting, feedback, action planning, etc. The phone counselling will be provided during the first six months, i.e. 6 phone calls will be delivered.
Study NCT05351359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit tracker
Description: Fitbit Inspire 2 will be provided by the general practitioner to study participants at the start of the study to enable objective self-monitoring of physical activity.
Study NCT05616468 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BGT007 Cell Injection
Description: BGT007 cells (d0) were infused intravenously once, and the dose group was 5.0 × 10\^5cells/kg，1.0 × 10\^6cells/kg，3.0 × 10\^6cells/kg，6.0 × 10\^6cells/kg，1.0 × 10\^7cells/kg。
Study NCT05616468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25\~30mg/m2/d was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
Study NCT05616468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 250\~350mg/m2/d cyclophosphamide was infused intravenously for 3 consecutive days. (- 5 days to - 3 days)
Study NCT05189548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
Description: A single-center and single-arm design was used to evaluate the safety and preliminary immunogenicity of the adsorbed cell-free leukiche (three-component) combination vaccine
Study NCT05351359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit tracker
Description: Fitbit Inspire 2 will be provided by the general practitioner to study participants at the start of the study to enable objective self-monitoring of physical activity.
Study NCT05351359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brief advice
Description: A brief advice will be provided by the general practitioner at the start of the study.
Study NCT05351359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brief advice
Description: A brief advice will be provided by the general practitioner at the start of the study.
Study NCT05180695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.
Study NCT05180695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Description: Part 1: A dose escalation part with the aim to assess the safety of the proposed combination. Eligible patients will be treated with a fixed dose of pazopanib (800mg/d, continuously) and escalating doses of HDM201. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.~Part 2: An extension part with a fixed dose of pazopanib (800mg/d, continuously) and the recommended phase 2 dose of HDM201 determined during the dose escalation part. Both study drugs will be administered as long as the patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression or withdrawal of consent.
Study NCT05353595 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Insect protein
Description: Insect protein concentrate retrieved from lesser mealworms.
Study NCT05353595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Running exercise
Description: 40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak
Study NCT05353595 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Running exercise
Description: 40 minutes of running on a treadmill at 70% heart rate corresponding Vo2peak
Study NCT05936008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise MICT
Description: Standard of care, exercise recommendations for people with stroke
Study NCT05936008 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise HIIT
Description: The HIIT protocol consists of Short Interval, High Volume exercise at 1-minute exercise bouts followed by 1-minute active recovery for 25 minutes.
Study NCT05444218 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Open flap debridement
Description: After local anesthesia (2% lidocaine with1:100,000 epinephrine), intrasulcular incisions will be performed to create a horizontal flap extending beyond the adjacent teeth and/or implants. Buccal and lingual full-thickness flaps will be dissected, and granulation tissue will be removed to expose the implant threads and bone defect. The flap will be repositioned in its original position and stabilized with interrupted sutures, which will be removed after 10 days.
Study NCT04899843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulphate tablet 20 mg
Description: Zinc sulphate tablet 20 mg daily orally for 8 weeks along with topical retinoids.
Study NCT04899843 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet 20 mg
Description: Placebo tablet 20 mg daily orally for 8 weeks along with topical retinoids
Study NCT05444218 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open flap debridement
Description: After local anesthesia (2% lidocaine with1:100,000 epinephrine), intrasulcular incisions will be performed to create a horizontal flap extending beyond the adjacent teeth and/or implants. Buccal and lingual full-thickness flaps will be dissected, and granulation tissue will be removed to expose the implant threads and bone defect. The flap will be repositioned in its original position and stabilized with interrupted sutures, which will be removed after 10 days.
Study NCT05444218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Er: YAG irradiation
Description: An Er:YAG laser (Lite Touch, Light Instruments, Israel) will be used, with an irradiation energy of 20 mJ, frequency of 20 Hz, output power of 0.4 W, and an energy density of 2.76 J/cm2. An 8 mm long sapphire tip will be used in the respective handpiece and not in contact with the titanium surface, with concomitant water spray irrigation, under air 6 and water spray 6, the irradiation angle will be 90 degrees, at a focal distance of 2 mm, with spot size diameter of 1.3 mm
Study NCT05444218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Er: YAG irradiation
Description: An Er:YAG laser (Lite Touch, Light Instruments, Israel) will be used, with an irradiation energy of 20 mJ, frequency of 20 Hz, output power of 0.4 W, and an energy density of 2.76 J/cm2. An 8 mm long sapphire tip will be used in the respective handpiece and not in contact with the titanium surface, with concomitant water spray irrigation, under air 6 and water spray 6, the irradiation angle will be 90 degrees, at a focal distance of 2 mm, with spot size diameter of 1.3 mm
Study NCT05444218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
Study NCT05444218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning after open flap debridement).
Study NCT05444218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (beginning after open flap debridement).
Study NCT06289933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR3005
Description: One tablet administered alone, Once a day
Study NCT04835337 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Air Purifiers
Description: Students are divided into two groups: intervention group and control group. The intervention team places an air purifier in the indoor environment to intervene. All the indoor environment of the group use the same qualified air purifier, and all participants and research staffs are blinded to the group assignment.
Study NCT04835337 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Air Purifiers
Description: The control group is also intervened. The intervention is to place a sham air purifier (remove the filter screen) in the indoor environment, and all the indoor environment use the same air purifier as the intervention group. All participants and research staffs are blinded to the group assignment.
Study NCT06155227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise combined with blood flow restriction
Description: aerobic exercise combined with blood flow restriction for 18 sessions
Study NCT06155227 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic exercise for 18 sessions
Study NCT04955340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-resminostat
Description: 1 single dose of 400 mg \[14C\]-resminostat
Study NCT06079125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior fossa decompression with duraplasty
Description: The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
Study NCT06079125 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PFDD with tonsillar resection/reduction
Description: The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. Then herniated tonsil will be manipulated and adhesion was released. After microsurgical manipulated, the dura is sewn closed with a dural graft.